|
|
|
|
|
|
Sponsors and Collaborators: |
Eisai Medical Research Inc. Teva Pharmaceutical Industries |
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00104273 |
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
Condition | Intervention | Phase |
Dementia Alzheimer's Disease |
Drug: Rasagiline |
Phase II |
Genetics Home Reference related topics: | Alzheimer disease |
MedlinePlus related topics: | Alzheimer's Disease Dementia |
ChemIDplus related topics: | Donepezil E 2020 Rasagiline Rasagiline mesylate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type |
Enrollment: | 376 |
Study Start Date: | August 2004 |
Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 45 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Use of any unapproved prior or concomitant medications, including:
Show 58 Study Locations |
Eisai Medical Research Inc. |
Teva Pharmaceutical Industries |
Study Director: | Timothy Hsu | Eisai Medical Research Inc. |
Study ID Numbers: | TVP-1012-A001-201 |
First Received: | February 24, 2005 |
Last Updated: | April 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00104273 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|